Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. - Archive ouverte HAL Access content directly
Journal Articles Stem Cells and Development Year : 2013

Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.

(1, 2) , (3) , (3) , (1) , (3) , (1, 2) , (3) , (3) , (2) , (4) , (5) , (4) , (1) , (3)
1
2
3
4
5

Abstract

Clinical-grade mesenchymal stromal cells (MSCs) are usually expanded from bone marrow (BMMSCs) or adipose tissue (ADSCs) using processes mainly differing in the use of fetal calf serum (FCS) or human platelet lysate (PL). We aimed to compare immune modulatory properties of clinical-grade MSCs using a combination of fully standardized in vitro assays. BMMSCs expanded with FCS (BMMSC-FCS) or PL (BMMSC-PL), and ADSC-PL were analyzed in quantitative phenotypic and functional experiments, including their capacity to inhibit the proliferation of T, B, and NK cells. The molecular mechanisms supporting T-cell inhibition were investigated. These parameters were also evaluated after pre-stimulation of MSCs with inflammatory cytokines. BMMSC-FCS, BMMSC-PL, and ADSC-PL displayed significant differences in expression of immunosuppressive and adhesion molecules. Standardized functional assays revealed that resting MSCs inhibited proliferation of T and NK cells, but not B cells. ADSC-PL were the most potent in inhibiting T-cell growth, a property ascribed to interferon-γ-dependent indoleamine 2,3-dioxygenase activity. MSCs did not stimulate allogeneic T cell proliferation but were efficiently lysed by activated NK cells. The systematic use of quantitative and reproducible validation techniques highlights differences in immunological properties of MSCs produced using various clinical-grade processes. ADSC-PL emerge as a promising candidate for future clinical trials.
Fichier principal
Vignette du fichier
inserm-00799812_edited.pdf (486.2 Ko) Télécharger le fichier
Vignette du fichier
scd.2012.pdf (1.2 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Loading...

Dates and versions

inserm-00799812 , version 1 (25-02-2014)

Identifiers

Cite

Cedric Menard, Luciano Pacelli, Giulio Bassi, Joelle Dulong, Francesco Bifari, et al.. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls.. Stem Cells and Development, 2013, 22 (12), pp.1789-801. ⟨10.1089/scd.2012.0594⟩. ⟨inserm-00799812⟩
381 View
1031 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More